Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus

Amit Kaushik, Chhavi Gupta, Stefanie Fisher, Elizabeth Story-Roller, Christos Galanis, Nicole Parrish, Gyanu Lamichhane

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates. Materials & methods: 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined. Results: Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam. Conclusion: Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections.

Original languageEnglish (US)
Pages (from-to)473-480
Number of pages8
JournalFuture microbiology
Volume12
Issue number6
DOIs
StatePublished - May 2017

Keywords

  • Mycobacterium abscessus
  • avibactam
  • carbapenem
  • ertapenem
  • panipenem
  • tebipenem

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus'. Together they form a unique fingerprint.

Cite this